newsletter masthead
September 20, 2018
MESSAGE FROM THE DIRECTOR
Dr. Stan Gerson Stan Gerson, MD
Director, Case Comprehensive Cancer Center

Conflict of Interest
The New York Times recently ran a story about a top cancer researcher who failed to disclose corporate financial ties in many of his research publications. The article outlines the researcher's relationship with corporations, making the point that " [the researcher's] extensive corporate relationships - and his frequent failure to disclose them - illustrate how permeable the boundaries remain between academic research and industry, and how weakly reporting requirements are enforced by the medical journals and professional societies charged with policing them." This is not the impression we want to convey to the public. 

In her weekly message , Dean Pamela Davis, dean of the  Case Western Reserve University School of Medicine, addressed this issue and reminded the audience that it is our duty as researchers to ensure the results we produce are honest and transparent. 

" We deal with the lives and health of human beings -therefore it is crucial that the science is accurate and the interpretations impeccable. Anything less than absolute integrity puts patients at risk," said Davis. "Beyond accurate data and reporting, we owe our patients and the scientific community full disclosure about information that may affect how we interpret our findings. Journal readers must be able to consider any possible biases that could influence our data analysis and interpretation. Meticulous attention to these precepts creates public confidence in our findings and recommendations."

This is a great reminder to review your conflict of interest policies. 
Cleveland Biden Cancer Community Summit
Sep 21, 2019 | Facebook Live
Facebook Live promo - Sep 2018 Tune in this Friday, September 21 at 10am EST for a  Facebook Live event to get a behind-the-scenes look at how Case Comprehensive Cancer Center researchers right here in Cleveland area exploring new ways to detect and treat cancer. Presented in collaboration with ideastream, host  Marlene Harris-Taylor will take you inside a lab with  Dr. Justin Lathia from the Cleveland Clinic Lerner Research Institute and  Dr. Anant Madabhushi from Case Western Reserve University Department of Biomedical Engineering. These two researchers and their teams with show you how they are using innovative techniques to help unlock some of the mysteries of this disease.

Biden Community Summit This event is part of a national movement of Cancer Community Summits all taking place on September 21. We are one of more than 450 sites across the world that answered the Biden's call to share updates and discuss our local efforts to accelerate progress in cancer diagnosis, treatment and care.
We encourage you to watch the  Facebook Live event, and forward to hearing your questions and comments LIVE!

Click here to view the Facebook event page. Mark yourself as "going" to receive updates and a reminder when the event starts.
MEMBER/CENTER HIGHLIGHTS
Jordan M. Winter, MD, appointed Chief of Surgical Oncology and Director of Surgical Services
Jordan Winter Jordan M. Winter, MD, has been appointed Chief of the Division of Surgical Oncology at University Hospitals Cleveland Medical Center and Director of Surgical Services at UH Seidman Cancer Center

"Dr. Winter is recognized nationally for his clinical, teaching and research expertise in pancreatic cancer," said Ted Teknos, MD, President of the UH Seidman Cancer Center and Deputy Director for University Hospitals, Case Comprehensive Cancer Center. "His achievements reflect a deep commitment to aid patients and families facing the most challenging cancers while helping colleagues and clinicians in training achieve their professional goals."

In addition to surgical management of pancreatic and related cancers, he treats other upper gastrointestinal malignancies and abdominal tumors. He has authored more than 100 peer-reviewed articles and a dozen book chapters, many of them on pancreatic cancer. more>
Khalil Receives NIH Funding to Develop New Paradigm in Fight against Colorectal Cancer
Ahmad Khalil Certain genes that code for proteins have long been known to contribute to cancer progression. But in a frame shift, researchers from the Case Comprehensive Cancer Center  recently found that non-coding genes also contribute to the development and spreading of the disease, one of the first known examples of researchers doing so.

The lead author of the study reporting this finding, Ahmad Khalil, PhD, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine, has been awarded a five-year, $1.85 million grant from the National Institutes of Health to build on the discovery, with an eventual aim of pinpointing additional targets for cancer-fighting treatments.

Under the new grant, Khalil, who is also a member of the Case Comprehensive Cancer Center, will seek to learn how non-coding genes work in the progression of colorectal cancer. This knowledge could then be applied to devising new therapies for the disease, which is the second leading cause of cancer-related deaths among cancers that affect both men and women in the United States. more>
Zhou Receives $2M NIH Grant to Study Colorectal Cancer Development
Lan Zhou Lan Zhou, MD, PhD, associate professor of pathology at Case Western Reserve University School of Medicine, has received a five-year, $2 million grant from the National Cancer Institute of the National Institutes of Health to study human colorectal cancer. Her work focuses on the effect of the imbalance of the gut microbiome, the immune response, and genetics in the development of adenocarcinoma (cancer that forms in the lining of the glands) through the serrated pathway.

The "serrated pathway" is a molecular pathway postulated for a subset of colorectal cancers that develop from certain serrated adenomas/polyps-growths that have a saw-tooth appearance when viewed under the microscope. It is distinct from the conventional adenoma-carcinoma (cancer) pathway, which involves "flat" growths. As many as 15 percent of all colorectal cancers start from serrated adenoma polyps with dysplasia (cells that look distinctively abnormal under the microscope). Serrated lesions are also found in patients with irritable bowel disease and colitis, often contributing to colon cancer development in that population. Serrated cancer lesions are not well described, do not respond well to chemotherapy compared to other tumors, and are associated with worse prognoses. more>
Case Western Reserve Researchers Accurately Predict How Well Body Will Fight Lung Cancer Based on Patterns of Immune Cells
Researchers at Case Western Reserve University have discovered how to quickly and accurately predict which lung cancer patients will benefit from chemotherapy by analyzing how immune cells the body sends out to fight the disease are arranged.

The scientists-aided by smart-imaging computers and machine-learning methods-were able to swiftly analyze hundreds of tissue images to not only count cancer-associated immune cells-but identify patterns in how they were arranged.

That breakthrough view can now help determine which patients need chemotherapy or immunotherapy based on computational analysis of routine tissue-slide images obtained either by surgery or biopsy, said Anant Madabhushi, the F. Alex Nason Professor II of biomedical engineering and member of the Case Comprehensive Cancer Center.

"We believe we've made a critical advance to the field with this work," said Madabhushi, the lead among a dozen authors  on a recent paper [ Corredor, Clin Cancer Res, 2018] about the work. "Do you need chemo or not?-that's the direct benefit to the patient and what really matters."

While this published research focused on early-stage lung cancer tissue, further analysis also predicted the success of immunotherapy in late-stage lung cancer, Madabhushi said. more>
Wynshaw-Boris Elected President of the American Society of Human Genetics
Anthony Wynshaw-Boris Anthony Wynshaw-Boris, MD, PhD, the James H. Jewell MD '34 Professor of Genetics and chair of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center and Rainbow Babies & Children's Hospital, and member of the Case Comprehensive Cancer Center, has been elected as president of the American Society of Human Genetics, the primary professional membership organization for human genetics worldwide.

Wynshaw-Boris will serve as president-elect in 2019, president in 2020, and past president in 2021.
Prostate Cancer Fellows Receive Department of Defense Grants
Sharifi-Alyamani-Bohn photo Mohammad Alyamani, PhD, and Kelsey Bohn, PhD  received Department of Defense (DoD) Prostate Cancer Research Program Early Investigator Research Awards. Alyamani and Bohn are both postdoctoral fellows in the laboratory of Nima Sharifi, MDDepartment of Cancer Biology at Cleveland Clinic and leader of the GU Malignancies Program of the Case Comprehensive Cancer Center. These prestigious awards will enable Drs. Alyamani and Bohn to contribute to the lab's innovative prostate cancer research while launching their own independent research careers. more>
MARK YOUR CALENDARS
3rd Annual Cancer Disparities Symposium
Mar 1, 2019 | Tinkham Veale University Center

The 3rd Annual Cancer Disparities Symposium will be held Friday, Mar 1, 2019. 

2019 Symposium Highlights
  • Keynote presentations by renowned disparities researchers and community leaders
  • Scientific Keynote presentation by Rick Kittles, PhD, Associate Director of Health Equities, Comprehensive Cancer Center; Professor and Director, Division of Health Equities, Department of Population Sciences, City of Hope
  • Poster session highlighting academic research and community programs
  • Networking session
  • All attendee forum
Call for Abstracts
The Case Comprehensive Cancer Center invites multidisciplinary researchers, community agencies and organizations to submit abstracts for presentation at the 3rd Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for oral presentations. 

Abstracts must be submitted via email ( caseccc-ocdr@case.edu) by 5pm EST on December 4, 2018.

Cancer Center Seminar Series
Sep 28, 12p | WRB 1-413

pasquale Join us Friday, September 28 at 12p in the WRB 1-413 to hear invited speaker, Elena B. Pasquale, PhD, present " Diversification of EphA2 receptor signaling in cancer by ligands and S/T kinases." Dr. Pasquale is Professor and Director, Academic Affairs, Sanford Burnham Prebys Medical Discovery Institute. This seminar is p resented by the Molecular Oncology Program of the Case Comprehensive Cancer Center. 

Dr. Pasquale was among the first to study protein tyrosine phosphorylation in normal cells. She discovered that this phosphorylation is elevated in early embryos and devised a strategy to uncoverthe kinases responsible. This identified novel tyrosine kinases, including FGFand Eph receptors.  Dr.  Pasquale has elucidated key signaling mechanisms involved in Eph receptor-dependent regulation of neural function and cancer malignancy. Translational aspects of herresearch include development of Eph receptor-targeting peptides.

NOTE: Tomorrow's speaker, Dr. Manning, had to postpone his seminar presentation. There will be no Seminar tomorrow, September 21. 
Midwest Association of Core Directors Annual Meeting
Oct 24-26, 2018 | Tinkham Veale University Center
Midwest Association of Core Directors Case Western Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner Research Institute (LRI) is hosting the 9th annual meeting of the Midwest Association of Core Directors, the regional chapter of the Association of Biomolecular Resource Facilities.

This three-day conference will be held in the Tinkham Veale University Center on CWRU campus, and will feature both introductory ("101-level") and state of the science-level breakout meetings on genomics, mass spec, imaging, administration, drug discovery, entrepreneurship, and RNA sciences. Plus, the agenda is packed with keynote talks, problem solving sessions, satellite workshops, and core facility tours both at CWRU and LRI. 

The entire research community is invited and encouraged to attend this conference - membership in the ABRF is not required. The School of Medicine Office of Research Administration is covering 50% of the $160 registration fee for any CWRU-SOM Employee (Faculty, Staff, Students, Post Docs). Please contact Matt DeVries ( mpd35@case.edu ) for the discount code. We look forward to seeing you all there! 
IN THE NEWS
Written by  Pamela B. Davis, MD, PhD,  Dean, School of Medicine, Case Western Reserve University,  Cleveland
We were pleased to learn that one of our very own Cleveland natives, Ellen Ziffren, helped establish Stand Up to Cancer (SU2C), one of the nation's foremost cancer research philanthropies (The Plain Dealer, August 29, 2018).  As a top Ohio cancer research institution, we shares SU2C's commitment to team science to defeat this insidious disease. In April, 2017, we were honored by having members of our faculty and the Case Comprehensive Cancer Center named to the organization's Colorectal Cancer Dream Team, receiving a prestigious award from the SU2C and the American Association for Cancer Research.  One example of our team's promising research is conducted in the laboratory of Zhenghe John Wang, PhD, who is working on a promising approach that starves colorectal cancer cells by depriving them of a critical nutrient, glutamine, with the aim of killing the harmful cells.
News-Medical - Sep 7, 2018
Dr. Paul Tesar  from the  TESAR Laboratory  at CWRU School of Medicine and Case Comprehensive Cancer Center, discusses the importance of organoids in biological research and the development of organoids which are capable of simulating the early stages of human myelin.
NIH BULLETIN- Notices and Funding Opportunities
rfas 
Notices
Notice of Change to Key Dates in PAR-18-249 "Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01 Clinical Trial Optional)"(NOT-CA-18-093)

Notice of Pre-Application Technical Assistance Webinar for RFA-MD-18-011, Limited Competition: RCMI Research Coordination Network (RRCN) (U54 Clinical Trial Not Allowed)(NOT-MD-18-016) 

Requests for Applications
Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)(RFA-CA-18-029)
Deadline: Nov 15, 2018

Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Coordinating Center (DMACC) (U24 Clinical Trials Required)(RFA-CA-18-030)
Deadline: Nov 15, 2018

Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional)(RFA-CA-19-001)
Deadline: January 9, 2019

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not Allowed)(RFA-CA-19-016) 
Deadline: December 7, 2018

Program Announcements
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)(PA-18-917)
Deadline: Standard dates

Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Trial Optional)(PAR-18-919)
Deadline: Standard dates
IN THIS ISSUE
EVENTSevents
Fri, Sep 21
Hem Onc Division Research Conference
Mara Beveridge, MD
Clinical Assistant Professor, Dermatology, CWRU/UHCMC
"Supportive Oncodermatology: Recognizing and treating skin toxicities of anti-cancer therapy"
8a Wearn 137

Cleveland Biden Cancer Community Summit
10a Facebook Live

Cellular and Molecular Medicine
Atul Chopra
CWRU
"Human genetics aided discovery of a new metabolic hormone"
10a NC1-202

Cancer Center Seminar Series CANCELLED 
12p WRB 1-413
Tues, Sep 25
Cancer Imaging Monthly Meeting
Ethan Walker, PhD
Professor, Biomedical Engineering, CWRU
1:30p WRB 1422-D
Thurs, Sep 27
Developmental Therapeutics Journal Club
9a R4-013 Cleveland Clinic

Molecular Biology & Microbiology Seminar
Mikael Garabedian
1p 
Fri, Sep 28
Taussig Cancer Institute Grand Rounds
Nancy Kemeny, MD
Memorial-Sloan Kettering
"The treatment of colorectal liver metastases: The role of regional therapy"
8a CA5-120 Cleveland Clinic

Cancer Center Seminar Series
Elena B. Pasquale,  PhD
Professor and Director, Academic Affairs, Sanford Burnham Prebys Medical Discovery Institute
"Diversification of EphA2 receptor signaling in cancer by ligands and S/T kinases"
12p WRB 1-413
Mon, Oct 1
Genomic Medicine Institute
Ata Abbas, PhD
Eng Lab, Genomic Medicine Institute, Cleveland Clinic
"PTEN regulates global transcription by redistributing genome-wide RNA polymerase II occupancy"
12p NE1-205 Cleveland Clinic

Cancer Center Research Chalk Talk
Liraz Levi, PhD
CWRU
1p WRB 3-136
Tues, Oct 2
Cancer Center Research in Progress Seminar
3p WRB 3-136
Thurs, Oct 4
Developmental Therapeutics Journal Club
9a R4-013 Cleveland Clinic
Fri, Oct 5
Developmental Therapeutics Journal Club
8a CA5-120 Cleveland Clinic

Cellular and Molecular Medicine
John Turchi, PhD
Tom & Julia Woof Family Foundation Chair in Lung Cancer Research
Indiana University
"Drugging the DNA damage response: Novel targets and therapeutic strategies"
10a NC1-202

Cancer Center Seminar Series
Jill Barnholtz-Sloan, PhD
Associate Director for Bioinformatics/Translational Informatics
Sally S. Morley Designated Professor in Brain Tumor Research
Case Comprehensive Cancer Center and Cleveland Institute for Computational Biology
Director, Research Health Analytics and Informatics, University Hospitals Health System (UHHS)
Director, Cleveland Center for Health Outcomes Research (CCHOR), CWRU
"Leveraging BIG DATA for novel cancer discoveries"
12p WRB 1-413

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285